VistaGen Licenses Regenerative Medicine Technology To BlueRock Therapeutics
Thursday, December 15, 2016 10:41 AM EDT
The agreement provides some nice potential upside in terms of future milestones and royalties from BlueRock. It also provides VistaGen a roadmap to monetize other aspects of its hPSC platform for cell therapy and regenerative medicine applications.
In this article: VTGN